<DOC>
	<DOCNO>NCT01380236</DOCNO>
	<brief_summary>The purpose study determine safety tolerability 8.0 mg ASM8 give daily 14 day Aeroneb® Go nebulizer subject moderate severe asthma .</brief_summary>
	<brief_title>A Single Blind Study Evaluate Safety , Tolerability Explore Efficacy 8.0 mg ASM8 Inhaled Daily 14 Days Severe Asthma</brief_title>
	<detailed_description>The safety tolerability ASM8 assess perform physical exam vital sign , measure use concomitant medication , routine laboratory test , urinalysis , sputum analysis , serum IL-1 TNF-α , lung carbon monoxide diffusion capacity , pulse oximetry measure AEs There 5 study phase : screening ( phase 1 ) , run-in ( phase 2 ) , treatment A ( phase 3 ) Active Placebo , treatment B ( phase 4 ) Active Placebo end study ( phase 5 ) include wash period final visit .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Be diagnose asthma 3 month Have moderate severe asthma define ATS criteria No history pulmonary health problem Investigator considers participation protocol risk subject</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>